Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

This study has been completed.
Aventis Pharmaceuticals
Genentech, Inc.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: June 7, 2005
Last updated: February 23, 2012
Last verified: February 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2011
  Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)